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Abstract
Background: In the phase III ASCLEPIOS I and II trials, participants with relapsing multiple sclerosis
receiving ofatumumab had significantly better clinical and magnetic resonance imaging (MRI) outcomes
than those receiving teriflunomide.
Objectives: To assess the efficacy and safety of ofatumumab versus teriflunomide in recently diagnosed,
treatment-naive (RDTN) participants from ASCLEPIOS.
Methods: Participants were randomized to receive ofatumumab (20 mg subcutaneously every 4 weeks)
or teriflunomide (14 mg orally once daily) for up to 30 months. Endpoints analysed post hoc in the protocol-defined RDTN population included annualized relapse rate (ARR), confirmed disability worsening
(CDW), progression independent of relapse activity (PIRA) and adverse events.
Results: Data were analysed from 615 RDTN participants (ofatumumab: n = 314; teriflunomide: n = 301).
Compared with teriflunomide, ofatumumab reduced ARR by 50% (rate ratio (95% confidence interval
(CI)): 0.50 (0.33, 0.74); p < 0.001), and delayed 6-month CDW by 46% (hazard ratio (HR; 95% CI): 0.54
(0.30, 0.98); p = 0.044) and 6-month PIRA by 56% (HR: 0.44 (0.20, 1.00); p = 0.049). Safety findings
were manageable and consistent with those of the overall ASCLEPIOS population.
Conclusion: The favourable benefit–risk profile of ofatumumab versus teriflunomide supports its consideration as a first-line therapy in RDTN patients.
ASCLEPIOS I and II are registered at ClinicalTrials.gov (NCT02792218 and NCT02792231).

Introduction
In young adults, MS is the most common chronic,
inflammatory, demyelinating and neurodegenerative
CNS disease,1 and is a leading cause of non-traumatic
disability.2 In patients with relapsing MS (RMS), disability accrual was previously thought to be a sequential process, driven by poor recovery from relapses
during the initial relapsing stage, followed by relapseindependent progression in the secondary progressive
stage.3 However, accumulating clinical evidence indicates that relapses with incomplete recovery and
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progression independent of relapse activity (PIRA)
both contribute to disability accrual from disease
onset, albeit in different proportions.4–6 Consistent
with PIRA occurring from MS onset, findings from
neuropathology, biomarker and imaging studies suggest that neuroaxonal loss, the main driver of neurodegeneration and irreversible progression in advanced
MS, may already be prominent in early RMS.7–9
Younger patients with RMS have higher clinical and
MRI disease activity, as well as more pronounced
acute axonal damage,7 than older patients.10 Moreover,
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neuronal and brain volume loss begin early in the
disease.11,12 High levels of disability, high lesion load
and low brain volume are associated with poor MS
prognosis.13
The effect of disease-modifying therapies (DMTs) on
worsening of MS disability is age-dependent, with
younger patients and those earlier in the disease course
showing the greatest benefit.10,14–16 Therefore, early
treatment with high-efficacy DMTs that can slow disability accrual is essential.17,18 However, there are barriers to early intervention with high-efficacy DMTs.
Uncertainty early in the disease course regarding MS
severity means that some patients are reluctant to
accept long-term treatment with any DMT, including
high-efficacy DMTs. Also, safety concerns may cause
clinicians to delay high-efficacy DMT use, resulting
in subclinical CNS damage compromising repair and
compensation capacity, poor symptom control and
eventually accrual of irreversible disability. Moreover,
some high-efficacy therapies are restricted to later
treatment lines by regulators, payers and healthcare
management organizations.
Ofatumumab, a fully human anti-CD20 monoclonal
antibody that selectively depletes B cells,19 is approved
in the USA, across Europe and in several other countries for the treatment of adults with RMS.20,21 In the
ASCLEPIOS I and II phase III trials, ofatumumab
(20 mg subcutaneously every 4 weeks) was superior
to teriflunomide (14 mg orally once daily) in participants with RMS, significantly reducing relapse rate,
disability worsening and MRI lesion activity with a
favourable safety and tolerability profile that allowed
for home administration without premedication.22
The ASCLEPIOS trials and comparison across trials
via network meta-analyses have shown that ofatumumab is among the most highly efficacious treatments for MS.22,23
In this study, we assessed the benefit–risk profile of
ofatumumab versus that of teriflunomide, analysing
clinical and MRI data in a subpopulation of participants with early RMS (recently diagnosed and treatment-naive (RDTN)) from the combined ASCLEPIOS
I and II trial populations.
Methods
Trial design and participants
Details of the ASCLEPIOS I (ClinicalTrials.gov
identifier: NCT02792218) and II (NCT02792231)
trials have been reported.22 ASCLEPIOS I and II
were randomized, double-blind, double-dummy,
journals.sagepub.com/home/msj

active-controlled, multicentre trials of identical design
conducted concurrently in participants with RMS.
Participants were randomized (1:1) to ofatumumab
20 mg subcutaneously every 4 weeks (starting at
week 4, after initial dosing of 20 mg on days 1, 7 and
14) or teriflunomide 14 mg orally once daily for up to
30 months.22 Protocols were approved by the relevant
institutional review board or ethics committee at
each trial site, and all participants provided written
informed consent.
Analysis populations
Unless otherwise specified, analyses were performed
in the protocol-defined RDTN subpopulation of participants from the pooled full analysis set (FAS; all
randomized participants with assigned treatments)
from ASCLEPIOS I and II. The full inclusion and key
exclusion criteria for the FAS in ASCLEPIOS I and
II are listed in Supplementary Text 1. This subpopulation was defined as those participants who
had received an RMS diagnosis within the 36-month
period before screening and had no prior treatment
with a DMT. As reported elsewhere,24 a modified FAS
was used for the analysis of no evidence of disease
activity (NEDA) and it included all participants in the
FAS according to the intent-to-treat principle, but
excluded those who discontinued treatment early for
reasons other than ‘lack of efficacy’ or ‘death’ and
who had NEDA before early discontinuation. The
safety set included all participants who received trial
drugs.
Endpoints and definitions
Efficacy endpoints to assess the benefit–risk of
ofatumumab versus teriflunomide treatment were:
annualized relapse rate (ARR); confirmed disability
worsening (CDW) at 3 months (3mCDW) and at
6 months (6mCDW); PIRA at 3 months (3mPIRA)
and at 6 months (6mPIRA); the number of gadoliniumenhancing (Gd+) T1 lesions per MRI scan; the number of new or enlarging T2 lesions per year; annual
rate of brain volume loss; the three-parameter NEDA
(NEDA-3); and neurofilament light chain (NfL) concentration. Quantitation of NfL in human serum was
done using the Quanterix Simoa NF-light assay
advantage kit, which is a two-step quantitative digital
immunoassay. A technical assessment was performed
to validate the performance claims of the Quanterix
Simoa NfL kit in a serum matrix for use as a clinical
trial assay.
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ARR was the number of confirmed MS relapses
observed on the study, standardized to 1 year. 3mCDW
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and 6mCDW were increased from baseline Expanded
Disability Status Scale (EDSS) score (by ⩾1.5 points
for a score of 0, by ⩾1 point for scores of 1–5 and by
⩾0.5 points for a score ⩾5.5) sustained for at least 3
or 6 months, respectively; 3mPIRA and 6mPIRA used
the same EDSS criteria as 3mCDW and 6mCDW, but
included only cases in which the onset of progression
did not occur during an investigator-reported relapse.
NEDA-3 criteria were no confirmed relapses, no
6mCDW and no MRI activity (i.e. Gd+T1 lesions or
enlarging T2 lesions on any MRI scan vs. baseline).
Safety endpoints to assess the benefit–risk of ofatumumab versus teriflunomide treatment were adverse
events (AEs), AEs leading to study discontinuation,
and serious AEs (SAEs); AEs were recorded at all
visits and graded using the Common Terminology
Criteria for Adverse Events.25

a repeated-measures model after log-transformation
of the data; the treatment effect (i.e. percentage reduction in NfL concentration) was the ratio of geometric
means (ofatumumab vs. teriflunomide) × 100.
Safety data were collected during the treatment
period (screening to the end of the trial) and the
safety follow-up period until a participant’s last visit.
After the last treatment dose, participants were followed up for at least 9 months. Data collected on or
before 100 days after the last dose of study medication were included in the analysis except for SAEs,
for which all data collected until the end of the trial
were included.
Analyses of individual endpoints in RDTN participants were undertaken post hoc.
Results

Statistical analyses
Participant characteristics at baseline were summarized descriptively by treatment in the RDTN subpopulation and in the pooled FAS. Percentage compliance
was calculated in the safety set as the duration of
exposure to study drug (days)/treatment duration
(days).
ARR was analysed using a negative binomial regression model, with an offset to adjust for variable study
duration in years. Disability-related endpoints (CDW
and PIRA) were analysed using a Cox proportional
hazards model. 3mPIRA and 6mPIRA were analysed
in: (1) RDTN participants with no confirmed on-study
relapses and (2) RDTN participants with no confirmed relapses on study or before a CDW event.
More stringent sensitivity analyses of these two
groups included only participants without confirmed
or unconfirmed on-study relapses, and with CDW
defined such that confirmation could not be within
90 days of a relapse. Numbers of Gd+T1 lesions and
of new or enlarging T2 lesions were assessed using
negative binomial regression models; the number of
available MRI scans was the offset for analysis of
Gd+T1 lesions; and the time in years between baseline scan and last available scan was the offset for
analysis of T2 lesions. The annual rate of brain volume loss was estimated as the marginal slope estimate
from a random coefficient model with random intercept and slope based on assessments of brain volume
percentage change from baseline at month 12,
month 24 and end of treatment and/or trials.
NEDA-3 was analysed in the modified FAS using
logistic regression. Serum NfL concentration was
measured at months 3, 12 and 24, and analysed using
1564

Participants
Of the 1882 participants randomly assigned to treatment in ASCLEPIOS I and II, 615 (32.7%) were
RDTN (ofatumumab, 314; teriflunomide, 301). RDTN
participants had a median of 0.35 and 0.36 years from
diagnosis for the ofatumumab and teriflunomide treated
patients, respectively, with a range of 0.1–2.9 years
from diagnosis for both groups. Demographic and
disease characteristics were similar between treatment groups and across trials (Table 1). Comparison
by treatment group with the overall ASCLEPIOS
population showed that RDTN participants in both
groups were – as expected – younger with lower disability scores and lower total T2 lesion volume.
The median duration of exposure to study treatment
was 1.7 years for those receiving ofatumumab, and
1.6 years for those receiving teriflunomide. 90% of
patients received study treatment for more than 1 year,
and more than 25% of participants received treatment
for more than 2 years (Supplementary Figure 1).
Compliance in RDTN participants was high (ofatumumab, 98.8%; teriflunomide, 98.9%), 100% compliance being achieved by 171 of 314 (54.5%) and
176 of 301 (58.5%) in the two groups, respectively; at
least 90% compliance was achieved by 307 of 314
(97.8%) ofatumumab-treated participants.
Efficacy in RDTN participants
Ofatumumab reduced ARR by 50% versus teriflunomide (ARR: 0.09 vs. 0.18; rate ratio (95% confidence
interval; CI): 0.50 (0.33, 0.74); p < 0.001) (Table 2).
journals.sagepub.com/home/msj
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Table 1. Participant characteristics and demographics in RDTN participants and in the overall population from the
ASCLEPIOS I and II trials (FAS).
Characteristic

Age, mean (SD)b, years
Women, n (%)
Type of MS, n (%)
RRMS
SPMS
Time since diagnosis, mean (SD), years
Relapses in previous 12 months, mean (SD)
Relapses in previous 12–24 months, mean (SD)
EDSS score at baseline, mean (SD)c
Participants with Gd+T1 lesions, mean (SD)
Participants with Gd+T1 lesions, n (%)
Total volume of T2 lesions, mean (SD), cm3
NfL concentration, mean (SD), pg/mL
Normalized brain volume, mean (SD), cm3

RDTN participants from
ASCLEPIOS I and IIa

All participants from
ASCLEPIOS I and II

Ofatumumab
(n = 314)

Teriflunomide
(n = 301)

Ofatumumab
(N = 946)

Teriflunomide
(N = 936)

36.8 (9.4)
217 (69.1)

35.7 (9.0)
195 (64.8)

38.4 (9.0)
637 (67.3)

38.0 (9.2)
636 (67.9)

311 (99.0)
3 (1.0)
0.58 (0.63)
1.3 (0.7)
0.6 (0.8)
2.30 (1.20)
n = 306
1.8 (4.4)
141 (44.9)
n = 311
10.11 (12.23)
n = 297
15.19 (18.57)
n = 310
1472.6 (72.3)

296 (98.3)
5 (1.7)
0.53 (0.51)
1.4 (0.7)
0.5 (1.0)
2.28 (1.20)
n = 298
1.4 (2.8)
130 (43.2)
n = 300
8.31 (8.83)
n = 279
13.66 (14.52)
n = 300
1472.9 (66.1)

890 (94.1)
56 (5.9)
5.68 (6.21)
1.2 (0.7)
0.8 (1.0)
2.93 (1.35)
n = 923
1.7 (4.5)
385 (40.7)
n = 934
13.72 (13.80)
n = 893
13.98 (15.86)
n = 929
1439.8 (78.9)

884 (94.4)
52 (5.6)
5.56 (6.10)
1.3 (0.7)
0.9 (1.1)
2.90 (1.37)
n = 922
1.3 (3.4)
352 (37.6)
n = 930
12.55 (13.81)
n = 853
12.54 (11.94)
n = 927
1444.0 (77.8)

EDSS: Expanded Disability Status Scale; FAS: full analysis set; Gd+: gadolinium-enhancing; NfL: neurofilament light chain;
RDTN, recently diagnosed, treatment-naive; RRMS: relapsing–remitting MS; SD: standard deviation; SPMS: secondary
progressive MS.
Unless otherwise stated in individual rows, the number of participants with available data at baseline is indicated in the column
header.
aRDTN were those who had not received a prior MS disease-modifying therapy and who had received a diagnosis in the 36 months
before screening.
bAge at baseline was calculated from the date of the first administration of trial drug and the birth year (no exact birth date was
captured for data privacy reasons). Eligibility for trial entry was assessed at the screening visit.
cEDSS score at baseline was defined as the EDSS score at the last assessment before administration of the first dose of trial drug.
EDSS scores range from 0 to 10.0, with higher scores indicating a higher degree of disability.

Ofatumumab reduced the risk of 3mCDW numerically by 38% (hazard ratio (HR) (95% CI): 0.62 (0.37,
1.03); p = 0.065) and of 6mCDW by 46% (HR (95%
CI): 0.54 (0.30, 0.98); p = 0.044) versus teriflunomide
(Figure 1 and Table 2).
Over half of all 3mCDW events (ofatumumab,
13/24; teriflunomide, 20/37) and 6mCDW events
(ofatumumab, 9/17; teriflunomide, 17/30) occurred
in the absence of confirmed on-study relapses and
were considered PIRA. In the subgroup of participants without confirmed on-study relapses, the proportion of participants with 3mPIRA events was
numerically lower, and the proportion with 6mPIRA
events significantly lower, with ofatumumab than
with teriflunomide (3mPIRA: 6.6% vs. 9.1%; HR
(95% CI): 0.55 (0.27, 1.11); p = 0.096); 6mPIRA:
3.6% vs. 7.7%; HR (95% CI): 0.44 (0.20, 1.00);

journals.sagepub.com/home/msj

p = 0.049) (Figure 2(a) and (b)). The findings in the
subgroup without confirmed on-study relapses
before 3mPIRA or 6mPIRA events were similar and
significant (3mPIRA: 6.9% vs. 10.2%; HR (95%
CI): 0.51 (0.26, 1.00); p = 0.049; 6mPIRA: 4.0% vs.
8.9%; HR (95% CI): 0.41 (0.19, 0.89); p = 0.023)
(Figure 2(c) and (d)). In the sensitivity analyses
(with PIRA defined such that CDW could not be
within 90 days of a relapse), the hazard of a 3mPIRA
and 6mPIRA event was numerically lower with ofatumumab than with teriflunomide (3mPIRA, HR
(95% CI): 0.62 (0.27, 1.43); p = 0.263; 6mPIRA, HR
(95% CI): 0.55 (0.23, 1.36); p = 0.197). Findings in
the subgroup of participants without any confirmed
on-study relapses before 3mPIRA or 6mPIRA were
similar (3mPIRA, HR (95% CI): 0.63 (0.28, 1.40);
p = 0.254; 6mPIRA, HR (95% CI): 0.57 (0.24, 1.33);
p = 0.194).
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Table 2. Clinical, MRI and biomarker outcomes in the subpopulation of RDTN participants from the ASCLEPIOS I and II trials (FAS).
Outcome

RDTN participantsa
Ofatumumab

Relapses
No. of participants evaluated
Total no. of relapses
No. of patient-years
Adjusted ARR (95% CI)
Rate ratio (95% CI)
Disability-related outcomes
3mCDW
   No. of events during the trial/no. of participants (%)
   HR (95% CI)
6mCDW
   No. of events during the trial/no. of participants (%)
   HR (95% CI)
MRI-related outcomes
Gd+T1 lesions
   No. of participants evaluated
   No. of Gd+lesions
   No of evaluable scans
   Mean no. of lesions per scan (95% CI)
   Rate ratio (95% CI)
New or enlarging T2 lesions
   No. of participants evaluated
   No. of new or enlarging T2 lesions
   No. of patient-years
   Mean no. of lesions per year (95% CI)
   Rate ratio (95% CI)
Brain volume change
   No. of participants evaluated
   Annual rate of changeb (95% CI)
   Difference in percentage points (95% CI)
NEDA-3
Months 0–12
  No. of participants achieving NEDA-3/no. of participantsc (%)
   Odds ratio (95% CI)
Months 12–24
  No. of participants achieving NEDA-3/no. of participantsc (%)
   Odds ratio (95% CI)
Months 0–24
  No. of participants achieving NEDA-3/no. of participantsc (%)
   Odds ratio (95% CI)
Biomarker outcomes
Serum NfL concentration
  At 3 months
    No. of participants evaluated
    Geometric mean (95% CI), pg/mL
    Geometric mean ratio (95% CI)

Teriflunomide

p value

314
301
45
88
509
494
0.09 (0.07, 0.12)
0.18 (0.14, 0.23)
0.50 (0.33, 0.74)

24/312 (7.7)

17/312 (5.4)

<0.001

37/300 (12.3)
0.62 (0.37, 1.03)

0.065

30/300 (10.0)
0.54 (0.30, 0.98)

0.044

296
284
10
212
561
540
0.02 (<0.01, 0.04)
0.39 (0.28, 0.53)
0.05 (0.02, 0.10)

<0.001

300
287
418
2179
481
469
0.86 (0.70, 1.05)
4.78 (3.97, 5.76)
0.18 (0.14, 0.24)

<0.001

295
280
–0.30 (–0.37, –0.23)
–0.31 (–0.38, –0.24)
0.01 (–0.10, 0.11)

0.9

134/285 (47.0)

258/280 (92.1)

127/285 (44.6)

71/288 (24.7)
3.31 (2.24, 4.90)

<0.001

131/280 (46.8)
14.68 (8.76, 24.61)

<0.001

51/288 (17.7)
4.63 (3.05, 7.03)

<0.001

294
280
8.72 (8.20, 9.26)
9.13 (8.58, 9.72)
0.95 (0.88, 1.03)

0.258
(Continued)
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Table 2. (Continued)
Outcome

RDTN participantsa
Ofatumumab

  At 12 months
    No. of participants evaluated
    Geometric mean (95% CI), pg/mL
    Geometric mean ratio (95% CI)
  At 24 months
    No. of participants evaluated
    Geometric mean (95% CI), pg/mL
    Geometric mean ratio (95% CI)

Teriflunomide

p value

285
274
6.60 (6.25, 6.98)
8.61 (8.14, 9.11)
0.77 (0.71, 0.83)

<0.001

254
253
6.47 (6.11, 6.85)
8.10 (7.64, 8.58)
0.80 (0.74, 0.86)

<0.001

3mCDW: 3-month confirmed disability worsening; 6mCDW: 6-month confirmed disability worsening; ARR: annualized relapse rate; CI: confidence interval;
FAS: full analysis set; Gd+: gadolinium-enhancing; HR: hazard ratio; NEDA: no evidence of disease activity; NfL: neurofilament light chain; RDTN:
recently diagnosed, treatment-naive.
aRDTN participants were those who had not received a prior disease-modifying therapy and who had received a diagnosis in the 36 months before screening.
bThe annual rate of brain volume change was estimated according to the slope from a random coefficient model based on assessment of the percentage change
from baseline in brain volume performed at month 12, month 24 and the end of treatment and/or trial.
cThe total number of participants in the treatment group for whom the response variable was defined.

MRI-related outcomes. Ofatumumab reduced the
mean number of Gd+T1 lesions per scan from baseline to the end of the trial by 95% versus teriflunomide
(0.02 vs. 0.39; rate ratio (95% CI): 0.05 (0.02, 0.10);
p < 0.001) (Table 2; Figure 3). Ofatumumab also
reduced the annualized rate of new or enlarging T2
lesions by 82% versus teriflunomide (Table 2). There
was no between-group difference in annual percentage
change in brain volume from baseline (Table 2).
No evidence of disease activity 3. Ofatumumab significantly increased the odds of achieving NEDA-3
versus teriflunomide in all study periods evaluated
(Table 2). The proportions of ofatumumab-treated and
teriflunomide-treated participants achieving NEDA-3
were: 47.0% and 24.7% in year 1, 92.1% and 46.8%
in year 2 and 44.6% and 17.7% from baseline through
year 2, respectively.
Serum NfL concentration. There was no significant
difference in mean serum NfL concentration with
ofatumumab and teriflunomide at month 3 (8.72
vs. 9.13 pg/mL; ratio (95% CI): 0.95 (0.88, 1.03);
p = 0.258) (Table 2). However, mean serum NfL concentration was significantly lower (both p < 0.001) in
the ofatumumab group than in the teriflunomide group
at month 12 (6.60 vs. 8.61 pg/mL; ratio (95% CI):
0.77 (0.71, 0.83)) and month 24 (6.47 vs. 8.10 pg/mL;
ratio (95% CI): 0.80 (0.74, 0.86)) (Table 2).
Safety in RDTN participants
Safety outcomes are summarized in Table 3; similar
proportions of participants experienced AEs in both
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treatment groups (ofatumumab, 84.7%; teriflunomide, 86.0%). AEs that occurred in at least 10% of
participants with ofatumumab were nasopharyngitis,
injection-related systemic reactions, headache and
upper respiratory tract infections; and with teriflunomide were nasopharyngitis, alopecia, upper respiratory tract infection, injection-related systemic
reactions, headache and fatigue. SAEs were reported
in 22 participants (7.0%) receiving ofatumumab and
16 (5.3%) receiving teriflunomide. There were no
deaths.
Injection-related reactions. Injection-related systemic
reactions were reported for 62 participants (20.1%)
receiving ofatumumab and 45 participants (15.0%) in
the teriflunomide group receiving placebo injections. Incidence of injection-site reactions was 14.0%
(n = 44) and 7.0% (n = 21), respectively. After the first
injection, the frequency of injection-related systemic reactions was similar in both groups (Figure 4).
Nearly all (99.4%) injection-related reactions (systemic and site) were mild to moderate in severity (no
Grade 4 injection-related reactions were reported).
Only one participant receiving ofatumumab experienced a Grade 3, non-serious injection-related
systemic reaction and discontinued the study treatment. This participant experienced abdominal pain,
asthenia, pruritis general and urticaria that resolved
within 1 day after treatment with an antihistamine. No
anaphylaxis related to ofatumumab treatment was
observed. Participants received training and selfadministered ofatumumab at day 7, day 14 and month
1 visits, under the supervision of a healthcare provider. From the fifth injection, 48–95% of participants
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Figure 1. Kaplan–Meier estimates of percentage of patients with disability worsening confirmed at: (a) 3 and (b)
6 months.
Disability worsening confirmed at 3 or 6 months was defined as an increase from baseline in the Expanded Disability Status Scale
(EDSS) score (on a scale from 0 to 10.0, with higher scores indicating worse disability) that was sustained for at least 3 or 6 months. For
patients with a baseline EDSS score of 0, an increase in the EDSS score of at least 1.5 points was required; for patients with a baseline
EDSS score of 1.0 to 5.0, the criterion was an increase of at least 1.0 points; and for patients with a baseline EDSS score of at least 5.5
points, the criterion was an increase of at least 0.5 points.

self-injected at home, increasing to 60%–95% from
injection 10 onwards.
Infections. Similar proportions of participants in
both treatment groups experienced infections (ofatumumab, 56.1%; teriflunomide, 56.5%) (Table 3).
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Nasopharyngitis and upper respiratory tract infection
were the most common and were mostly mild to moderate in severity. Six participants (1.9%) receiving
ofatumumab and two (0.7%) receiving teriflunomide
had serious infections. No opportunistic infections
were reported.
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Figure 2. Kaplan–Meier analyses of time to PIRA in RDTN participants: (a) time to 3mPIRA in participants without
confirmed relapses on study, (b) time to 6mPIRA in participants without confirmed relapses on study, (c) time to 3mPIRA
in participants without confirmed relapses on study or before 3mCDW and (d) time to 6mPIRA in participants without
confirmed relapses on study or before 6mCDW.
3mCDW: 3-month confirmed disability worsening; 3mPIRA: 3-month progression independent of relapse activity; 6mCDW: 6 month
confirmed disability worsening; 6mPIRA: 6-month progression independent of relapse activity; PIRA: progression independent of
relapse activity; RDTN: recently diagnosed, treatment-naive.

Other safety findings. Two malignancies (0.6%) were
reported in the ofatumumab group, and one (0.3%) in
the teriflunomide group (all basal cell carcinomas). No
congenital abnormalities or birth defects were reported
among participants exposed to either treatment during
pregnancy (ofatumumab, two participants; teriflunomide, three participants). Neutropenia, a known risk
associated with teriflunomide, occurred more frequently in the teriflunomide group (four participants)
than in the ofatumumab group (two participants).

achieved for 90% of patients by week 4, and 98% of
patients by week 12 (Supplementary Figure 2). The
effect of ofatumumab on B-cell depletion was consistent across body weight quartiles. After the last ofatumumab dose in participants who stopped treatment
for any reason, B-cell repletion (levels above the
LLN) was observed in 12 of 27 participants (44%) by
week 24, 13 of 21 (62%) by week 36, 6 of 8 (75%) by
week 48 and 8 of 8 (100%) by week 60.

B- cell levels. B-cell depletion to below the lower limit
of normal (LLN) (40 cells/µL) was achieved quickly
with ofatumumab. By week 2, 97% of participants
had B-cell levels below the LLN and this proportion
remained constant until the end of the trial. B-cell
depletion of less than or equal to 10 cells/µL was

Discussion
In RDTN participants from the phase III ASCLEPIOS
I and II trials, ofatumumab was superior to teriflunomide in reducing relapse rates, delaying all-cause
disability worsening, including PIRA, with a nearcomplete abrogation of new focal inflammatory
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Figure 3. Empirical lesion incidence maps for Gd+T1 lesions in all RDTN participants: (a) at baseline (N = 615);
(b) 12 months after initiation of treatment with ofatumumab (N = 314); and (c) 12 months after initiation of treatment
with teriflunomide (N = 301).
Gd+, gadolinium-enhancing; RDTN: recently diagnosed, treatment-naive.
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Table 3. AEs in RDTN participants from the ASCLEPIOS I and II trials (safety analysis set).
Safety event

Ofatumumab (N = 314)

Teriflunomide (N = 301)

AEs
AEs leading to treatment discontinuation
Most common AEs (⩾10% in any group)
Nasopharyngitis
Injection-related systemic reaction
Headache
Upper respiratory tract infection
Fatigue
Alopecia
Infections (all)
SAEs
Infectionsa
Malignancy
Deaths

266 (84.7)
19 (6.1)

259 (86.0)
7 (2.3)

78 (24.8)
63 (20.1)
45 (14.3)
40 (12.7)
28 (8.9)
16 (5.1)
176 (56.1)
22 (7.0)
6 (1.9)
2 (0.6)b
0 (0.0)

70 (23.3)
45 (15.0)
47 (15.6)
49 (16.3)
30 (10.0)
50 (16.6)
170 (56.5)
16 (5.3)
2 (0.7)
1 (0.3)c
0 (0.0)

AE: adverse event; N: total number of participants included in the analysis; RDTN: recently diagnosed, treatment-naive; SAE:
serious AE.
Data are shown as the number of participants (%) with at least one event.
aThree cases of appendicitis, one case of influenza, one case of neutropenic sepsis, one case of upper respiratory tract infection in
the ofatumumab group, one case of appendicitis and one case of pneumonia in the teriflunomide group.
bAll malignancies were basal cell carcinomas.
cOne case of basal cell carcinoma was not listed as an SAE.

16
Proportion of participants (%)

14

Ofatumumab 20 mg

Grade 1

Grade 2

Teriflunomide 14 mg

Grade 1

Grade 2

Grade 3

12
10
8
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4
2
0
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310 301

No. of participants
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Injection number
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303 299

7
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9

10
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298 293

297 290

294 287

Figure 4. Proportion of RDTN participants with injection-related systemic reactions following the first 10 injections in
the study.
RDTN: recently diagnosed, treatment-naive.
Only Common Terminology Criteria for Adverse Events grades that were observed in the data are shown. Only reactions/symptoms
occurring within 24 hours after injections are included (i.e. time to onset of reaction ⩽ 24 hours).
As teriflunomide is taken as an oral medication, injection-related systemic reactions in participants treated with teriflunomide are in
response to placebo injections.

activity. These findings are consistent with those
observed in the overall ASCLEPIOS population22
and show that ofatumumab can delay disability worsening in early MS.
journals.sagepub.com/home/msj

Among patients early in the MS disease course, disability accrual was previously thought to be exclusively attributable to incomplete recovery from
relapses. However, in agreement with other studies of
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patients with RMS on DMT,4–6 we observed that,
when relapses and acute symptoms were suppressed,
proportionally more disability events occurred in the
form of progression events detected in the course of
regular 3-monthly neurological assessments by EDSS
raters blinded to treatment. In the RDTN group, most
patients (92.3% in the ofatumumab arm versus 87.7%
in the teriflunomide arm) remained clinically stable
and did not experience any 3mCDW events during
the entire study. Approximately half of the observed
CDW events in RDTN patients occurred in the
absence of overt relapses, although an effect of subclinical relapse biology cannot be ruled out.
Progression independent of relapse activity in early
relapsing–remitting MS is thought to be related to
neurodegenerative processes such as continuous
neuroaxonal damage and brain volume loss processes that have been shown to be present from the
initial stages of RMS.10,26 In patients with RMS, a
high baseline T2 lesion volume has been consistently
identified as an important risk factor for on-study
brain volume26 and neuronal27 loss. This suggests that
MS lesion prevention should be a target in the treatment of MS, as it is likely to underlie insidious disease progression.28,29
Ofatumumab delayed disability accrual compared
with teriflunomide in RDTN participants by reducing
the risk of CDW and PIRA, albeit not significantly in
sensitivity analyses that used a more rigorous definition of PIRA requiring no relapses within 90 days of
a disability event. The ASCLEPIOS studies were
powered to show an effect in the overall combined
trials, not in subgroups. Thus, the small sample size
and relatively low number of events using the more
stringent definitions may explain the lack of statistical significance despite a clinically meaningful effect
size.
The findings of this comparative analysis of ofatumumab versus teriflunomide efficacy in early RMS
are consistent with those from a network analysis
that suggested a benefit for ofatumumab versus other
first-line therapies.23 ARR comparisons in RDTN
participants suggest that, on average, patients would
experience neurological symptoms manifesting in
mostly temporary EDSS score changes once in
11 years with ofatumumab and once in 5.5 years with
teriflunomide. MRI findings indicate almost complete
abrogation of focal inflammatory disease with ofatumumab and a substantial associated reduction in
annual accrual of lesion burden. Consistent with these
clinical and radiological findings, RDTN participants
receiving ofatumumab had a 3 and 15 times greater
likelihood of achieving NEDA-3 during the first
1572

and second year of treatment, respectively, versus
teriflunomide. Notably, 9 of 10 ofatumumab-treated
participants achieved NEDA-3 during year 2, which
might better reflect the long-term preventive effect
on disease activity and worsening of disability.
Achieving NEDA-3 during the first 2 years of treatment has been associated with lower odds of disability
at 7–8 years.18,30
The safety and tolerability profile of ofatumumab in
RDTN participants was consistent with that in the
overall ASCLEPIOS population,22 with no safety
events that would prevent the use of ofatumumab
early in MS. Injection-related systemic reactions were
mostly mild to moderate and limited to the first injection with ofatumumab; reactions with subsequent
injections were largely similar to those observed with
placebo injections in the teriflunomide arm. After initial training, most participants self-injected at home.
The short-term safety and tolerability profile of ofatumumab also seems to compare favourably with that
of other treatments considered suitable for use in
early MS, such as interferon-β and glatiramer acetate, although long-term safety data for ofatumumab
are not yet available.31,32 Compliance with ofatumumab in RDTN participants was high, consistent
with the rates seen in the overall ASCLEPIOS I and
II population. The high compliance with ofatumumab
in this study lasting 30 months, as compared with
other injectable DMTs,33,34 might be explained by the
low frequency of injections and lack of need for
accompanying medications to prevent or mitigate
injection-related adverse events.
Conclusion
Ofatumumab had a superior benefit–risk profile in
RDTN patients compared with teriflunomide, with an
almost complete abrogation of inflammatory disease
activity and no unexpected safety signals, supporting
its use as a first-line treatment in early MS.
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